Adimmune to Supply Influenza Vaccine Antigen to Russia, Central Asia, and Eastern Europe

Adimmune Corporation (TPE: 4142) announced on 22nd it has signed a contract with Petrovax, a Russian vaccine manufacturer, for annual supplying antigen of quadrivalent influenza vaccine to be formulated, filled, and finished in Russia. 

This is Adimmune’s second international CDMO service to supply antigen of influenza vaccine after the first collaboration with Japan. Russia, adjacent to Eastern Europe, North Asia, and Central Asia, is regarded as the origin of several new variants of influenza. This represents a booming market of influenza vaccines in the area as well as new opportunities for Adimmune’s global growth.

Thanks to Adimmune’s GMP certifications from EU EMA and US FDA, the Russian competent authorities regarded an inspection at Adimmune to be unnecessary. Petrovax imported antigen of quadrivalent influenza vaccine and performed assays to make sure it conforms with regulatory standards. Trial production of influenza vaccines will be submitted this year for marketing authorization in Russia and approval is expected in 2022 before commercial-scale manufacturing commences. Petrovax plans to procure 100-300g of antigen of influenza vaccine for the first year of commercial production, and may further increase the quantity subject to market demands. 

On the other hand, Adimmune is delivering this year’s international orders of influenza vaccines to China, US, and Thailand. The shipments are expected to be completed before the end of this year.